{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-23-010655","form_type":"8-K","ticker":"ENVB","cik":"0000890821","company_name":"Enveric Biosciences, Inc.","filed_at":"2023-04-03T23:59:59+00:00","discovered_at":"2026-05-14T18:03:42.661609+00:00","generated_at":"2026-06-17T07:28:52.897235+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Enveric Biosciences reports FY2022 net loss of $19.3M; advances EB-373 toward Phase 1 in Q4 2023","bullets":["Comprehensive net loss $19.3M for FY2022 vs $48.8M in FY2021; diluted loss per share $13.00.","Cash and cash equivalents $17.7M, working capital $14.4M as of Dec. 31, 2022.","Lead candidate EB-373 nominated from EVM201 Series; Phase 1 trial planned for Q4 2023 in Australia.","Appointed Kevin Coveney as CFO and Lynn Gallant as VP Clinical Operations during year."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-23-010655","json":"https://secwatch.observer/filing/0001493152-23-010655.json","markdown":"https://secwatch.observer/filing/0001493152-23-010655.md","text":"https://secwatch.observer/filing/0001493152-23-010655.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/890821/000149315223010655/0001493152-23-010655-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/890821/000149315223010655/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-17T07:28:52.897235+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"b01a778cd4d4b716e058a37bbaf08200376ee60c","claim":"Enveric Biosciences, Inc. reported the fiscal year ended December 31, 2022 results: net income $19.3 million, EPS $13.00.","evidence_excerpt":"Comprehensive net loss was $19.3 million for the year ended December 31, 2022, including $2.4 million in net non-cash expenses, with a basic and diluted loss per share of $13.00","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/890821/000149315223010655/0001493152-23-010655-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fiscal year ended December 31, 2022"},{"label":"Net income","value":"$19.3 million"},{"label":"EPS","value":"$13.00"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}